search
Back to results

Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects

Primary Purpose

Overweight, Weight Loss

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
ProbioSatys™
Placebo
Sponsored by
TargEDys
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overweight focused on measuring Probiotics, Microbiome, Microbiota, Hafnia alvei, Overweight, Food intake, Appetite regulation, Satiety, Weight loss, Glucose Metabolism, Glycemia, Enterobacteriaceae, Gut-brain axis, Molecular mimicry

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18 to 65 years old males and females
  2. Overweight (Body Mass Index, BMI: 25 kg/m2 - 29.9 kg/m2)
  3. Generally in good health
  4. Desire to lose weight
  5. Regularly consuming 3 main meals/day (breakfast, lunch, dinner)
  6. Readiness to comply with study procedures, in particular:

    • Follow diet recommendation
    • Maintain the habitual level of physical activity during the study
    • Fill out the questionnaires and subject diary
    • Take the IP as instructed
  7. Stable body weight in the last 3 months prior to V1 (≤5% self-reported change)
  8. Stable concomitant medications (if any) for at least last 3 months prior to V1
  9. Women of childbearing potential:

    • Negative pregnancy testing (beta HCG-test in urine) at V1
    • Women of childbearing potential: commitment to use contraception methods (with the exception of starting new contraception medication)

Participation is based upon written informed consent form by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Randomisation criteria (to be checked after run-in at V2):

  1. No change in body weight or reduction up to 3 kg (compared to V1)
  2. Adequately completed subject diary
  3. Readiness and ability to comply with study requirements
  4. Relevant inclusion and exclusion criteria met

Exclusion Criteria:

  1. Known allergy/sensitivity to any components of the investigational product
  2. Pathological electrocardiogram (ECG) at V1
  3. History and/or presence of clinically significant self-reported disorder as per investigator's judgement:

    • Untreated or non-stabilised thyroid gland disorder
    • Untreated or non-stabilised hypertension (regular systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg)
    • Digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory bowel disease, coeliac disease, pancreatitis etc.) and/ or gastrointestinal surgery
    • Diabetes mellitus type 1 or untreated/non-stabilised type 2
    • Acute or chronic psychotic disorder
    • Immunodeficiency
    • Any other organ or systemic diseases that could influence the conduct and/or outcome of the study and/or could affect the tolerability of the subject
  4. History and/or presence of eating disorders like bulimia, anorexia nervosa, binge-eating as per investigator's judgement
  5. Any electronic medical implant
  6. Deviation of safety laboratory parameter(s) at V1 that is:

    • Clinically significant or
    • >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)
  7. Use of medication/supplementation in the last month prior to V1 and during the study, as per investigator's judgement:

    • That could influence gastrointestinal functions (such as antibiotics, probiotics, laxatives, opioids, anticholinergics, anti-diarrheals etc.)
    • For weight management (e.g. fat binder/burner, satiety products etc.)
    • That could influence body weight (e.g. antidepressants, systemic corticoids etc.)
    • That could otherwise interfere with study conduct / evaluation
  8. Diet/weight loss programs within the last 3 months prior to V1 and during the study
  9. Smoking cessation/modification of smoking level (if any) within 6 months prior to V1 and/or during the study (regular smoking during the study at the same level as prior to the study is allowed)
  10. Vegetarian, vegan or other restrictive diet
  11. Pregnancy or nursing
  12. History of or current abuse of drugs, alcohol or medication
  13. Inability to comply with study procedures
  14. Participation in another study during the last 30 days prior to V1
  15. Any other reason deemed suitable for exclusion, per investigator's judgment

Sites / Locations

  • Analyze & Realize
  • Barbara Grube
  • Jörg Förstermann

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ProbioSatys™

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")

Secondary Outcome Measures

Body weight change (in kg), compared to baseline (V2)
Body weight change (%), compared to baseline (V2)
Body weight (in kg )
Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")
Proportion of subjects who lost at least 5% of baseline body weight (="5% responders")
Body fat mass assessed per bioelectrical impedance analysis (BIA), compared to baseline
Body fat free mass assessed per bioelectrical impedance analysis (BIA), compared to baseline
Waist circumference, compared to baseline
Hip circumference, compared to baseline
Lipid metabolism parameters (total cholesterol), compared to screening values (V1)
Lipid metabolism parameters (high density lipid cholesterol), compared to screening values (V1)
Lipid metabolism parameters (low density lipid cholesterol), compared to screening values (V1)
Fasting glucose, compared to screening values (V1)
Glycated haemoglobin (HbA1c), compared to screening values (V1)
Evaluation of the overall feeling of satiety compared to baseline by using visual analogue scales (VAS)
continuous line between two endpoints: not saturated at all & fully saturated
Evaluation of the overall feeling of fullness compared to baseline by using visual analogue scales (VAS)
continuous line between two endpoints: not full at all & extremely full
Evaluation of the overall feeling of craving compared to baseline by using a 5 point Likert scale
0= "no", 1= "slightly", 2= "moderate", 3= "strong" and 4= "very strong"
General well-being parameters (Impact of Weight on Quality of Life-Lite, IWQOL-LITE), compared to baseline
Global evaluation of benefit at V5 by subject and the investigator
"very good", "good", "moderate" and "poor"

Full Information

First Posted
August 2, 2018
Last Updated
March 10, 2020
Sponsor
TargEDys
Collaborators
Analyze & Realize
search

1. Study Identification

Unique Protocol Identification Number
NCT03657186
Brief Title
Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects
Official Title
Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
August 31, 2018 (Actual)
Primary Completion Date
November 28, 2019 (Actual)
Study Completion Date
November 28, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TargEDys
Collaborators
Analyze & Realize

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters in overweight subjects during a 12-week consumption period. In addition, tolerability and safety of ProbioSatys™ will be assessed.
Detailed Description
ProbioSatys™ is a probiotic nutritional solution containing a commensal Enterobacteriaceae food grade strain, Hafnia alvei 4597. The microbiome is known to play a crucial role in body weight management and metabolic disease. ProbioSatys™ mechanism of action relies on bacterial metabolites that send local and central signals via the gut-brain axis by molecularly mimicking satiety hormones involved in appetite regulation. Numerous ProbioSatys™pre-clinical studies indicate that consumption of the strain leads to body weight loss based on food intake reduction, but also improvement of body composition (increase of lean mass/fat mass ratio), and improvement of glucose metabolism (oral glucose tolerance test, and fasted glycemia). The present study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters in overweight subjects during a 12-week consumption period. In addition, tolerability and safety of ProbioSatys™ will be assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Weight Loss
Keywords
Probiotics, Microbiome, Microbiota, Hafnia alvei, Overweight, Food intake, Appetite regulation, Satiety, Weight loss, Glucose Metabolism, Glycemia, Enterobacteriaceae, Gut-brain axis, Molecular mimicry

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
236 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ProbioSatys™
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
ProbioSatys™
Intervention Description
One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
Primary Outcome Measure Information:
Title
Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Body weight change (in kg), compared to baseline (V2)
Time Frame
4, 8 and 12 weeks
Title
Body weight change (%), compared to baseline (V2)
Time Frame
4, 8 and 12 weeks
Title
Body weight (in kg )
Time Frame
4, 8 and 12 weeks
Title
Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")
Time Frame
4 and 8 weeks
Title
Proportion of subjects who lost at least 5% of baseline body weight (="5% responders")
Time Frame
4, 8 and 12 weeks
Title
Body fat mass assessed per bioelectrical impedance analysis (BIA), compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Body fat free mass assessed per bioelectrical impedance analysis (BIA), compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Waist circumference, compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Hip circumference, compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Lipid metabolism parameters (total cholesterol), compared to screening values (V1)
Time Frame
14 weeks
Title
Lipid metabolism parameters (high density lipid cholesterol), compared to screening values (V1)
Time Frame
14 weeks
Title
Lipid metabolism parameters (low density lipid cholesterol), compared to screening values (V1)
Time Frame
14 weeks
Title
Fasting glucose, compared to screening values (V1)
Time Frame
14 weeks
Title
Glycated haemoglobin (HbA1c), compared to screening values (V1)
Time Frame
14 weeks
Title
Evaluation of the overall feeling of satiety compared to baseline by using visual analogue scales (VAS)
Description
continuous line between two endpoints: not saturated at all & fully saturated
Time Frame
4, 8 and 12 weeks
Title
Evaluation of the overall feeling of fullness compared to baseline by using visual analogue scales (VAS)
Description
continuous line between two endpoints: not full at all & extremely full
Time Frame
4, 8 and 12 weeks
Title
Evaluation of the overall feeling of craving compared to baseline by using a 5 point Likert scale
Description
0= "no", 1= "slightly", 2= "moderate", 3= "strong" and 4= "very strong"
Time Frame
4, 8 and 12 weeks
Title
General well-being parameters (Impact of Weight on Quality of Life-Lite, IWQOL-LITE), compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Global evaluation of benefit at V5 by subject and the investigator
Description
"very good", "good", "moderate" and "poor"
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Assessment of adverse events throughout the study
Time Frame
14 weeks
Title
Blood pressure, compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Pulse rate, compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
analysis of full blood count parameters (haemoglobin)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
analysis of full blood count parameters (haematocrit)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
analysis of full blood count parameters (thrombocytes)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
analysis of full blood count parameters (leucocytes)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (alanine transaminase)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (aspartate aminotransferase)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (gamma-glutamyltransferase)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (alkaline phosphatase)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (bilirubin)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (creatinine)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (urea)
Time Frame
14 weeks
Title
Safety laboratory parameters, compared to screening values (V1)
Description
liver and renal function parameters (uric acid)
Time Frame
14 weeks
Title
Global evaluation of tolerability at V5 by subject and the investigator
Description
"very good", "good", "moderate" and "poor"
Time Frame
12 weeks
Title
Gastrointestinal tolerability parameters (Gastrointestinal Symptom Rating Scale questionnaire, GSRS), compared to baseline
Time Frame
4, 8 and 12 weeks
Title
Stool frequency in the week before each visit post- baseline, each compared to the week before baseline (V2)
Time Frame
4, 8 and 12 weeks
Title
Physical activity parameters (Global Physical Activity Questionnaire, GPAQ), compared to baseline
Time Frame
4, 8 and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 to 65 years old males and females Overweight (Body Mass Index, BMI: 25 kg/m2 - 29.9 kg/m2) Generally in good health Desire to lose weight Regularly consuming 3 main meals/day (breakfast, lunch, dinner) Readiness to comply with study procedures, in particular: Follow diet recommendation Maintain the habitual level of physical activity during the study Fill out the questionnaires and subject diary Take the IP as instructed Stable body weight in the last 3 months prior to V1 (≤5% self-reported change) Stable concomitant medications (if any) for at least last 3 months prior to V1 Women of childbearing potential: Negative pregnancy testing (beta HCG-test in urine) at V1 Women of childbearing potential: commitment to use contraception methods (with the exception of starting new contraception medication) Participation is based upon written informed consent form by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study. Randomisation criteria (to be checked after run-in at V2): No change in body weight or reduction up to 3 kg (compared to V1) Adequately completed subject diary Readiness and ability to comply with study requirements Relevant inclusion and exclusion criteria met Exclusion Criteria: Known allergy/sensitivity to any components of the investigational product Pathological electrocardiogram (ECG) at V1 History and/or presence of clinically significant self-reported disorder as per investigator's judgement: Untreated or non-stabilised thyroid gland disorder Untreated or non-stabilised hypertension (regular systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) Digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory bowel disease, coeliac disease, pancreatitis etc.) and/ or gastrointestinal surgery Diabetes mellitus type 1 or untreated/non-stabilised type 2 Acute or chronic psychotic disorder Immunodeficiency Any other organ or systemic diseases that could influence the conduct and/or outcome of the study and/or could affect the tolerability of the subject History and/or presence of eating disorders like bulimia, anorexia nervosa, binge-eating as per investigator's judgement Any electronic medical implant Deviation of safety laboratory parameter(s) at V1 that is: Clinically significant or >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome) Use of medication/supplementation in the last month prior to V1 and during the study, as per investigator's judgement: That could influence gastrointestinal functions (such as antibiotics, probiotics, laxatives, opioids, anticholinergics, anti-diarrheals etc.) For weight management (e.g. fat binder/burner, satiety products etc.) That could influence body weight (e.g. antidepressants, systemic corticoids etc.) That could otherwise interfere with study conduct / evaluation Diet/weight loss programs within the last 3 months prior to V1 and during the study Smoking cessation/modification of smoking level (if any) within 6 months prior to V1 and/or during the study (regular smoking during the study at the same level as prior to the study is allowed) Vegetarian, vegan or other restrictive diet Pregnancy or nursing History of or current abuse of drugs, alcohol or medication Inability to comply with study procedures Participation in another study during the last 30 days prior to V1 Any other reason deemed suitable for exclusion, per investigator's judgment
Facility Information:
Facility Name
Analyze & Realize
City
Berlin
ZIP/Postal Code
10369
Country
Germany
Facility Name
Barbara Grube
City
Berlin
ZIP/Postal Code
10709
Country
Germany
Facility Name
Jörg Förstermann
City
Berlin
ZIP/Postal Code
14059
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects

We'll reach out to this number within 24 hrs